Dr. Reddy’s Laboratories announced that the FDA has approved Azacitidine for Injection, the generic version of Celgene’s Vidaza.

Vidaza is a cytidine analogue approved for use in myelodysplastic syndromes (eg, refractory anemias and chronic myelomonocytic leukemia). 

RELATED: Oncology Resource Center

Vidaza is believed to exert its antineoplastic effects by causing hypomethylation of DNA and direct cytotoxicity on abnormal hematopoietic cells in the bone marrow. This causes the death of rapidly dividing cells, including cancer cells that are no longer responsive to normal growth control mechanisms.

Azacitidine for Injection will be available in 100mg/vial in single-use vials. Dr. Reddy’s Laboratories plans to launch the product in the near future.

For more information call (908) 203-4900 or visit DrReddys.com.